RGPX · As filed with the SEC

Regenerex Pharma income statement, by quarter

The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

STATEMENTS OF OPERATIONS · USD, except per-share amounts

USD, except per-share amounts	Q2 FY25 3 months ended Sep 30, 2025	Q1 FY24 3 months ended Jun 30, 2025	Q4 FY24^† 3 months ended Mar 31, 2025	Q3 FY24 3 months ended Dec 31, 2024	Q2 FY24 3 months ended Sep 30, 2024	Q4 FY23^† 3 months ended Mar 31, 2024
Operating Expenses
Selling, General and Administrative Expense	650,277	633,783	356,825^†	294,130	258,384	280,344^†
Research and Development Expense	136,432	—	645,099^†	17,380	—	0^†
Total Operating Expenses	786,709	633,783	1,001,924^†	311,510	258,384	280,344^†
Operating Loss	(786,709)	(633,783)	(1,001,924)^†	(311,510)	(258,384)	(280,344)^†
Other Income (Expense)
Interest expense	(22,713)	(23,596)	(4,542)^†	(27,016)	(266,157)	(22,112)^†
Foreign currency gain (loss)	—	—	—	24,000	—	—
Foreign Currency Gain/Loss	(539)	(6,092)	—	—	(5,031)	—
Other expense	(4,000)	—	—	—	—	—
Income Tax Expense	(50)	(113)	—	—	—	—
Non-Operating Income (Expense)	(27,302)	(29,801)	(408,461)^†	(3,016)	(271,188)	(12,483)^†
Net Loss	(814,011)	(663,584)	(1,410,385)^†	(314,526)	(529,572)	(292,827)^†
Basic and Diluted Loss per Common Share	0.00	0.00	—	0.00	0.00	—
Weighted Average Shares Outstanding	281,463,410	281,123,410	—	278,436,236	278,281,562	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.